AI Summary Opdivo (nivolumab) is a PD-1 inhibitor immunotherapy used for advanced hepatocellular carcinoma that is not amenable to surgery or local therapies.
Medically reviewed.
Opdivo (nivolumab) is a prescription immunotherapy used to treat several cancers, including hepatocellular carcinoma (HCC). It is a PD-1 inhibitor, a medicine that helps overcome immune suppression within the tumor environment so immune cells can respond more effectively to cancer. Opdivo is used as a systemic treatment for advanced liver cancer. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Opdivo's role in liver cancer care: how it works, who may be eligible, how it is given, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Opdivo fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT OPDIVO TREATMENT
Opdivo is a prescription medicine that contains nivolumab. It belongs to a class of medications called PD-1 inhibitors, a type of immunotherapy. It is used to treat several cancers, including hepatocellular carcinoma (HCC).
Tumors can suppress the immune system around them. Opdivo helps overcome that suppression within the tumor environment, so immune cells can respond more effectively to cancer. In liver cancer, it is used for advanced HCC.
Opdivo is a systemic treatment, which means it treats cancer throughout the body. It is used as long-term therapy. A healthcare professional prepares and gives it, and your care team regularly monitors your response and checks for immune-related side effects. You can learn more about liver cancer and its treatment options on LiverDirectory.
WHO OPDIVO MAY BE SUITABLE FOR
Eligibility for Opdivo depends on your diagnosis, how advanced your cancer is, and your individual health needs. Your healthcare provider may prescribe Opdivo if you have advanced hepatocellular carcinoma, need systemic immunotherapy treatment, and your cancer is not amenable to surgery or local therapies.
Being a candidate for immune checkpoint inhibitor therapy is also part of the decision, as is whether your provider wants to improve immune-mediated tumor control. Your medical history, current health status, liver condition, and any other medications you take all factor into whether Opdivo is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Opdivo. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Opdivo may be considered for people with the following conditions or treatment goals:
Before recommending Opdivo, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW OPDIVO CAN HELP
Opdivo blocks the PD-1 immune checkpoint pathway. PD-1 is a signal on immune cells that tumors can use to switch off the body's response against them. By blocking this signal, Opdivo restores T-cell activity against cancer cells and enhances immune recognition of tumors.
As the immune response strengthens, cancer growth and progression may slow. In some people, Opdivo may produce durable treatment responses.
For people with advanced HCC, these effects support the goal of immune-mediated tumor control. Opdivo is given as a systemic therapy, and your care team pairs it with regular monitoring of your response and of immune-related adverse events.
LIVER CANCER CARE
Opdivo is a systemic immunotherapy for advanced hepatocellular carcinoma. Because it treats cancer throughout the body, it can be part of care when the disease is advanced.
When the cancer is not amenable to surgery or local therapies, Opdivo may give you and your care team another way to treat it.
Your healthcare provider may recommend Opdivo to improve immune-mediated tumor control and help slow the cancer's progression. In people who benefit, treatment may continue from several months to multiple years. Results vary from person to person.
Your care team regularly checks your response and looks for immune-related adverse events. Reporting symptoms early, such as a persistent cough, jaundice, diarrhea, or rash, helps them act quickly.
Opdivo can help in liver cancer care by offering a body-wide treatment for advanced disease, especially when surgery or local therapies are not options. Your care team guides and monitors the plan with you.
TREATMENT PROCESS
Opdivo is prepared and given by a healthcare professional. You do not prepare, handle, or store the medicine yourself.
For hepatocellular carcinoma, Opdivo may be given as 240 mg intravenously every 2 weeks or 480 mg intravenously every 4 weeks, depending on the regimen your healthcare provider selects.
Opdivo is given by IV infusion over approximately 30 minutes, according to prescribing guidelines. It is not a pill or an injection you give yourself.
Opdivo is used as long-term systemic therapy in advanced hepatocellular carcinoma. Treatment continues until the disease progresses, side effects become unacceptable, or your provider decides to stop. It varies widely and may range from several months to multiple years in people who benefit.
Healthcare professionals store and handle Opdivo. You do not need to store it at home.
Your healthcare provider will regularly monitor your response to treatment and check for immune-related adverse events. Report any side effects or unusual symptoms to your healthcare provider promptly.
BENEFITS AND SAFETY
Opdivo (nivolumab) may support people with advanced hepatocellular carcinoma by activating the immune system against cancer. It blocks PD-1 signaling on immune cells, and it may provide long-term disease control in some people. The extent of these benefits varies from person to person, depending on the cancer, overall health, and how the body responds to therapy. Opdivo is a systemic treatment, so it works throughout the body, and your care team monitors your response as part of a personalized plan.
As with any medication, Opdivo may cause side effects, ranging from fatigue and skin reactions to less common immune-related inflammation in organs such as the liver, lungs, or thyroid. Your healthcare provider will monitor your response and check for immune-related adverse events throughout treatment, and will assess whether Opdivo remains a suitable option for you.
BENEFITS
Opdivo is an immunotherapy, so it works by activating the immune system to fight cancer rather than by attacking the tumor directly. By enhancing immune recognition of tumors, it helps the body respond to the cancer more effectively.
Opdivo blocks PD-1 signaling on immune cells. Tumors can use this signal to switch off the body's response against them. Blocking it restores T-cell activity against cancer cells, which helps slow cancer growth and progression.
In some people, Opdivo may produce durable treatment responses, which means it may provide long-term disease control. In people who benefit, treatment may last from several months to multiple years. Outcomes vary by individual, depending on response and how well treatment is tolerated.
Opdivo treats cancer throughout the body. This makes it an option for advanced hepatocellular carcinoma that is not amenable to surgery or local therapies, when your provider wants to improve immune-mediated tumor control.
Tell your care team promptly about a persistent cough, shortness of breath, severe fatigue, jaundice, diarrhea, or rash, because these may signal immune-related inflammation. Your healthcare provider will discuss the potential benefits and risks before treatment and monitor you throughout.
SUPPORTING YOUR TREATMENT
Lifestyle habits do not replace Opdivo, but they help you stay well during treatment. Maintaining nutrition, hydration, and your infusion schedule is important, and prompt reporting of symptoms helps your care team act early.
Decreased appetite is a common side effect. Amsety Bars are nutrition bars designed for people with liver conditions. They can serve as a meal replacement or snack and support oral intake in people with poor appetites.
Areas that may support treatment:
common questions
Opdivo is used to treat advanced hepatocellular carcinoma (HCC) that is not amenable to surgery or local therapies. It contains nivolumab, a PD-1 inhibitor immunotherapy. It helps immune cells respond more effectively to cancer by overcoming immune suppression within the tumor environment. Opdivo is a systemic treatment, so it works throughout the body. Ask your healthcare professional whether it fits your diagnosis and treatment goals.
Opdivo may be considered for people with advanced hepatocellular carcinoma who need systemic immunotherapy and whose cancer is not amenable to surgery or local therapies. They should also be candidates for immune checkpoint inhibitor therapy. Your medical history, current health, liver condition, and other medications all matter. Eligibility is individual, so only your care team can decide after a full assessment. Talk with your healthcare professional about whether Opdivo fits your situation.
Opdivo blocks the PD-1 immune checkpoint pathway, a signal on immune cells that tumors can use to switch off the body's response. This restores T-cell activity against cancer cells and enhances immune recognition of tumors. As a result, cancer growth and progression may slow, and some people have durable treatment responses. Results vary from person to person. Your healthcare professional can explain what to expect in your case.
A healthcare professional gives Opdivo by IV infusion over approximately 30 minutes. For hepatocellular carcinoma, the dose may be 240 mg every 2 weeks or 480 mg every 4 weeks, depending on the regimen your provider selects. You do not prepare, handle, or store the medicine at home. Your care team sets the schedule, so follow their instructions and attend every infusion.
Opdivo treatment length varies widely, from several months to multiple years in people who benefit. It is long-term systemic therapy that continues until the disease progresses, side effects become unacceptable, or your provider decides to stop. Your care team regularly monitors your response and side effects to guide these decisions. Ask your healthcare professional what timeline is realistic for you.
The most common Opdivo side effects are fatigue, rash or itching, diarrhea, and decreased appetite. Opdivo can also cause immune-related inflammation in organs such as the liver, lungs, or thyroid. Tell your care team promptly about a persistent cough, shortness of breath, severe fatigue, jaundice, diarrhea, or rash, because these may signal inflammation. Your provider monitors you throughout treatment and can discuss benefits and risks with you.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
